Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Has Consensus Target Price of $377.20

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned a consensus recommendation of “Buy” from the fourteen research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $377.20.

KRYS has been the topic of several research reports. Jefferies Financial Group restated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, October 9th. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. The Goldman Sachs Group started coverage on shares of Krystal Biotech in a research report on Thursday, September 24th. They set a “buy” rating and a $441.00 target price for the company. Finally, Royal Bank Of Canada initiated coverage on Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price on the stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $330.00 on Tuesday. Krystal Biotech has a fifty-two week low of $183.03 and a fifty-two week high of $382.54. The firm has a market capitalization of $9.77 billion, a PE ratio of 41.35 and a beta of 0.50. The stock’s fifty day moving average is $340.61 and its 200 day moving average is $323.20.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. The business had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. Equities analysts forecast that Krystal Biotech will post 7.40 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 13.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

Several institutional investors have recently modified their holdings of the stock. Terra Nova Asset Management LLC purchased a new position in shares of Krystal Biotech in the third quarter worth about $828,000. GK Wealth Management LLC acquired a new position in shares of Krystal Biotech in the 3rd quarter worth approximately $59,000. GAMMA Investing LLC boosted its position in shares of Krystal Biotech by 10.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,100 shares of the company’s stock worth $366,000 after purchasing an additional 102 shares during the period. Toth Financial Advisory Corp lifted its stake in Krystal Biotech by 9.5% during the third quarter. Toth Financial Advisory Corp now owns 4,941 shares of the company’s stock worth $1,643,000 after purchasing an additional 430 shares in the last quarter. Finally, Congress Asset Management Co. grew its stake in shares of Krystal Biotech by 34.8% in the third quarter. Congress Asset Management Co. now owns 54,083 shares of the company’s stock valued at $17,986,000 after buying an additional 13,949 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.